AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05354765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression
Study NCT05354765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment
Study NCT06496945 — intervention group
Intervention type: OTHER
Intervention: Adult day program use
Description: Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
Study NCT06496945 — intervention group
Intervention type: OTHER
Intervention: Other community care (non-attendees)
Description: Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
Study NCT06311188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITR Healing intervention
Description: This is a nonrandomized test of the culturally adapted ITR healing intervention that is based on the ITR framework. The ITR Healing intervention comprises six 60-minute sessions based on Intersectionality theoretical framework, Healing Centered Engagement (HCE) activities that were integrated into the intervention, as well as participant's feedback about the intervention. Also, the participants' behavioral experiences per the Theoretical Domains Framework targets was used to adapt the intervention activities. HCE focuses on building a holistic approach and empathy for each session, i.e., using music, dance/movement, meditation, breathing and journaling.
Study NCT06545643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreem headband
Description: The Dreem headband is an EEG-based wearable tool that can be used to reliably assess the relationship between sleep and epilepsy over extended observation periods.
Study NCT05509309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APERS-based model
Description: APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
Study NCT05455619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evexomostat
Description: Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Study NCT05666206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fibrin sealant in hypospadias
Description: fibrin sealant will be used over the suture line
Study NCT05394207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. casei DG® (Lactobacillus paracasei CNCM I-1572)
Description: L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
Study NCT05394207 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
Study NCT04728815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU - Phase 1
Description: 4-8 weeks of TAU treatment
Study NCT04728815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 1
Description: 4-8 weeks of CAMS treatment
Study NCT04728815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT - Phase 1 and 2
Description: up to 16 weeks of DBT treatment
Study NCT04728815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS - Phase 2
Description: Up to 8 weeks of CAMS treatment
Study NCT04728815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT - Phase 2
Description: Up to 8 weeks of DBT treatment
Study NCT06246344 — intervention group
Intervention type: RADIATION
Intervention: MRI Guided Simultaneous Integrated Boost Radiotherapy
Description: MRI Guided Simultaneous Integrated Boost Radiotherapy
Study NCT05505539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given intralesionally by injection
Study NCT05229640 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
Study NCT06056401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: record Hemodynamic variables, respiratory variables and arterial blood gas at specific times
Description: Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
Study NCT04668547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic Embryolysis
Description: Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
Study NCT04381533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)
Description: The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
Study NCT04381533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation, information on use of alcohol and its effects
Description: The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
Study NCT05074394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-DROPS
Description: COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
Study NCT05074394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study NCT05193604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
Study NCT05193604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study NCT05193604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride for injection
Description: Chemotherapy medicine for metastatic pancreatic cancer
Study NCT05193604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound)
Description: Chemotherapy medicine for metastatic pancreatic cancer
Study NCT06189066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
Study NCT06263855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CURE
Description: A large language model (LLM) to help clinicians prepare discharge summaries for hospitalized patients.
Study NCT06424288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vicadrostat
Description: Vicadrostat
Study NCT06424288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT06424288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT06424288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 690517
Study NCT06284317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant durvalumab
Description: Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
Study NCT05860114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension~On days 1 and 13 givinostat was administered in the morning, following an overnight fasting of at least 8 hours and subjects remained fasted until at least 4 hours post-dose. Moreover the subjects were in a semi-recumbent position and remained semi-recumbent until at least 4 hours post-dose.No fluids were allowed from 1 hour before dosing until 2 hours post-dose. Water was provided ad libitum at all other times.~From Day 5 to Day 12, subjects received givinostat 50 mg as oral suspension, twice a day, in the morning and in the evening.
Study NCT05947331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Graded Anderson procedure
Description: In graded Anderson proceduren only recession of yoke muscles is done.
Study NCT05947331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kestenbaum procedure
Description: In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
Study NCT06280781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scans
Description: The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is >/=4.
Study NCT05947110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric-based hydro-kinesio therapy
Description: The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
Study NCT05947110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise therapy
Description: The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
Study NCT02312518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRP Concepts Fibrin Bio-Matrix
Description: PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
Study NCT02312518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual and Customary Practice
Description: Usual and Customary Practice for non-healing venous leg ulcers
Study NCT02312518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Practice
Description: Usual and Customary Practice for non-healing venous leg ulcers
Study NCT05109338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ben-Guard Garment
Description: Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
Study NCT05058040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oligomannate Capsules
Description: Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
Study NCT05819476 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: OLP-injection
Description: Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
Study NCT05819476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scripted Evidence-based treatment rationale
Description: As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
Study NCT05551260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition
Description: Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests
Study NCT05551260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition
Description: Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests
Study NCT05819476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental model of acute pain
Description: Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
Study NCT05478057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system
Description: we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
Study NCT05478057 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system
Description: we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
Study NCT05003934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT04863599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
Study NCT06159777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: \*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Study NCT06504407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bingo Educational Game
Description: The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
Study NCT05285137 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection
Study NCT05394012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3013
Description: Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
Study NCT05394012 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: Two doses of 30 μg/0.3 mL at an interval of 28 days
Study NCT04971993 — intervention group
Intervention type: DEVICE
Intervention: Wearable Cardiac Monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
Study NCT06159777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: \*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Study NCT05121792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy
Description: The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.